Reduction of breast density following tamoxifen treatment evaluated by 3-D MRI: Preliminary study

Magnetic Resonance Imaging

Volumn 29, Issue 1, 2011, Pages 91-98

  Chen, Jeon Hor ^a,b   Chang, Yeun Chung ^c   Chang, Daniel ^a   Wang, Yi Ting ^c   Nie, Ke ^a   Chang, Ruey Feng ^d   Nalcioglu, Orhan ^a   Huang, Chiun Sheng ^c   Su, Min Ying ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

3D MRI; Breast; Breast density; Fibroglandular tissue; Percent breast density; Tamoxifen

Indexed keywords

TAMOXIFEN;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; BREAST CANCER; BREAST DENSITY; BREAST SURGERY; BREAST VOLUME; CANCER RISK; CLINICAL ARTICLE; COMPUTER ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FIBROGLANDULAR TISSUE VOLUME; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; THREE DIMENSIONAL IMAGING; TREATMENT DURATION;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 78649930824     PISSN: 0730725X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mri.2010.07.009     Document Type: Article

References (50)

1. Boyd N.F., Guo H., Martin L.J., et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007, 356(3):227-236.
2. McCormack V.A., dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006, 15(6):1159-1169.
3. Vachon C.M., Pankratz V.S., Scott C.G., et al. Longitudinal trends in mammographic percent density and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2007, 16(5):921-928.
4. Yaffe M.J., Boyd N.F., Byng J.W., et al. Breast cancer risk and measured mammographic density. Eur J Cancer Prev 1998, 7(Suppl 1):S47-S55.
5. Boyd N.F., Dite G.S., Stone J., et al. Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med 2002, 347(12):886-894.
6. Boyd N.F., Byng J.W., Jong R.A., Fishell E.K., Little L.E., Miller A.B., et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995, 87:670-675.
7. Chen J., Pee D., Ayyagari R., et al. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst 2006, 98(17):1215-1226.
8. Santen R.J., Boyd N.F., Chlebowski R.T., et al. Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer 2007, 14(2):169-187.
9. Tice J.A., Cummings S.R., Ziv E., Kerlikowske K. Mammographic breast density and the Gail model for breast cancer risk prediction in a screening population. Breast Cancer Res Treat 2005, 94(2):115-122.
10. Tice J.A., Cummings S.R., Smith-Bindman R., Ichikawa L., Barlow W.E., Kerlikowske K. Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model. Ann Intern Med 2008, 148(5):337-347.
11. Hill-Kayser C.E., Harris E.E., Hwang W.T., Solin L.J. Twenty-year incidence and patterns of contralateral breast cancer after breast conservation treatment with radiation. Int J Radiat Oncol Biol Phys 2006, 66(5):1313-1319.
12. Tilanus-Linthorst M.M., Alves C., Seynaeve C., Menke-Pluymers M.B., Eggermont A.M., Brekelmans C.T. Contralateral recurrence and prognostic factors in familial non-BRCA1/2-associated breast cancer. Br J Surg 2006, 93(8):961-968.
13. Ji J., Hemminki K. Risk for contralateral breast cancers in a population covered by mammography: effects of family history, age at diagnosis and histology. Breast Cancer Res Treat 2007, 105(2):229-236.
14. Shahedi K., Emanuelsson M., Wiklund F., Gronberg H. High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma. Cancer 2006, 106(6):1237-1242.
15. Bao T., Prowell T., Stearns V. Chemoprevention of breast cancer: tamoxifen, raloxifene, and beyond. Am J Ther 2006, 13(4):337-348.
16. Ponzone R., Biglia N., Jacomuzzi M.E., Mariani L., Dominguez A., Sismondi P. Antihormones in prevention and treatment of breast cancer. Ann N Y Acad Sci 2006, 1089:143-158.
17. Cuzick J., Warwick J., Pinney E., Warren R.M., Duffy S.W. Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 2004, 96(8):621-628.
18. Eng-Wong J., Orzano-Birgani J., Chow C.K., et al. Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer. Cancer Epidemiol Biomarkers Prev 2008, 17(7):1696-1701.
19. Brisson J., Brisson B., Cote G., et al. Tamoxifen and mammographic densities. Cancer Epidemiol Biomarkers Prev 2000, 9:911-915.
20. Atkinson C., Warren R., Bingham S.A., Day N.E. Mammographic patterns as a predictive biomarker of breast cancer risk: effect of tamoxifen. Cancer Epidemiol Biomarkers Prev 1999, 8:863-866.
21. Son H.J., Oh K.K. Significance of follow-up mammography in estimating the effect of tamoxifen in breast cancer patients who have undergone surgery. AJR Am J Roentgenol 1999, 173:905-909.
22. de Souza Sales J.F., Cabello C., Alvarenga M., Torresan R.Z., Duarte G.M. Nonproliferative epithelial alteration and expression of estrogen receptor and Ki67 in the contralateral breast of women treated with tamoxifen for breast cancer. Breast 2007, 16(2):197-203.
23. Bernardes J.R., Nonogaki S., Seixas M.T., et al. Effect of a half dose of tamoxifen on proliferative activity in normal breast tissue. Int J Gynaecol Obstet 1999, 67(1):33-38.
24. da Silva B.B., Lopes I.M., Gebrim L.H. Effects of raloxifene on normal breast tissue from premenopausal women. Breast Cancer Res Treat 2006, 95(2):99-103.
25. Harvey J.A., Bovbjerg V.E. Quantitative assessment of mammographic breast density: relationship with breast cancer risk. Radiology 2004, 230:29-41.
26. Nie K., Chen J.H., Chan S., Chau M.K., Yu H.J., Bahri S., et al. Development of a quantitative method for analysis of breast density based on 3-dimensional breast MRI. Med Phys 2008, 35(12):5253-5262.
27. Habel L.A., Dignam J.J., Land S.R., Salane M., Capra A.M., Julian T.B. Mammographic density and breast cancer after ductal carcinoma in situ. J Natl Cancer Inst 2004, 96(19):1467-1472.
28. Maskarinec G., Pagano I., Lurie G., Kolonel L.N. A longitudinal investigation of mammographic density: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 2006, 15(4):732-739.
29. Kerlikowske K., Ichikawa L., Miglioretti D.L., et al. Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk. J Natl Cancer Inst 2007, 99(5):386-395.
30. Guthrie J.R., Milne R.L., Hopper J.L., Cawson J., Dennerstein L., Burger H.G. Mammographic densities during the menopausal transition: a longitudinal study of Australian-born women. Menopause 2007, 14(2):208-215.
31. Cuzick J., Warwick J., Pinney L., et al. Change in breast density as a biomarker of breast cancer risk reduction; results from IBIS-I 2008, Abstract 61.
32. Kopans D.B. Basic physics and doubts about relationship between mammographically determined tissue density and breast cancer risk. Radiology 2008, 246(2):348-353.
33. Khazen M., Warren R., Boggis C., et al. A pilot study of compositional analysis of the breast and estimation of breast mammographic density using three-dimensional T1-weighted magnetic resonance imaging. Cancer Epidemiol Biomarkers Prev 2008, 17(9):2268-2274.
34. Wei J., Chan H.P., Helvie M.A., et al. Correlation between mammographic density and volumetric fibroglandular tissue estimated on breast MR images. Med Phys 2004, 31(4):923-942.
35. van Engeland S., Snoeren P.R., Huisman H., Boetes C., Karssemeijer N. Volumetric breast density estimation from full-field digital mammograms. IEEE Trans Med Imaging 2006, 25(3):273-282.
36. Lee N.A., Rusinek H., Weinreb J., et al. Fatty and fibroglandular tissue volumes in the breasts of women 20-83 years old: comparison of X-ray mammography and computer-assisted MR imaging. AJR Am J Roentgenol 1997, 168:501-506.
37. Yao J., Zujewski J.A., Orzano J., Prindiville S., Chow C. Classification and calculation of breast fibroglandular tissue volume on SPGR fat suppressed MRI. Med Imag Proc SPIE 2005, 1942-1949.
38. Klifa C., Carballido-Gamio J., Wilmes L., et al. Quantification of breast tissue index from MR data using fuzzy cluster. Proc IEEE Eng Med Biol Soci 2004, 3:1667-1670.
39. Klifa C., Carballido-Gamio J., Wilmes L., et al. Magnetic resonance imaging for secondary assessment of breast density in a high-risk cohort. Magn Reson Imaging 2009, [Epub ahead of print].
40. Meggiorini M.L., Labi L., Vestri A.R., Porfiri L.M., Savelli S., De Felice C. Tamoxifen in women with breast cancer and mammographic density. Eur J Gynaecol Oncol 2008, 29(6):598-601.
41. Chow C.K., Venzon D., Jones E.C., et al. Effect of tamoxifen on mammographic density. Cancer Epidemiol Biomarkers Prev 2000, 9(9):917-921.
42. Briest S., Stearns V. Tamoxifen metabolism and its effect on endocrine treatment of breast cancer. Clin Adv Hematol Oncol 2009, 7(3):185-192.
43. Oktem O., Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer 2007, 110(10):2222-2229.
44. Gadducci A., Cosio S., Genazzani A.R. Ovarian function and childbearing issues in breast cancer survivors. Gynecol Endocrinol 2007, 23(11):625-631.
45. Swain S.M., Land S.R., Ritter M.W., et al. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. Breast Cancer Res Treat 2009, 113:315-320.
46. Heinig A., Lampe D., Kölbl H., Beck R., Heywang-Köbrunner SH Suppression of unspecific enhancement on breast magnetic resonance imaging (MRI) by antiestrogen medication. Tumori 2002, 88(3):215-223.
47. Oksa S., Parkkola R., Luukkaala T., Mäenpää J. Breast magnetic resonance imaging findings in women treated with toremifene for premenstrual mastalgia. Acta Radiol 2009, 50(9):984-989.
48. Cubuk R., Tasali N., Narin B., Keskiner F., Celik L., Guney S. Correlation between breast density in mammography and background enhancement in MR mammography. Radiol Med 2010, [Epub ahead of print].
49. Francucci C.M., Daniele P., Iori N., Camilletti A., Massi F., Boscaro M. Effects of raloxifene on body fat distribution and lipid profile in healthy post-menopausal women. J Endocrinol Invest 2005, 28(7):623-631.
50. Nguyen M.C., Stewart R.B., Banerji M.A., Gordon D.H., Kral J.G. Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancer. Int J Obes Relat Metab Disord 2001, 25(2):296-298.